Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Passage BioPASG +0.50%30 Debt-to-Equity is 0.49 as of Mar. 2026, which is 96% above its 10-year median of 0.25. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, Passage Bio ranks worse than 74.84% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Passage Bio's Debt-to-Equity or its related term are showing as below:
PASG'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.25 Max: 1.28
Current: 0.49
During the past 8 years, the highest Debt-to-Equity Ratio of Passage Bio was 1.28. The lowest was 0.10. And the median was 0.25.
PASG's Debt-to-Equity is ranked worse than 74.84% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs PASG: 0.49
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Passage Bio Debt-to-Equity Related Terms
Passage Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Passage Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PASG vs CTXR, HIND, GTBP: Debt-to-Equity Comparison
For the Biotechnology subindustry, Passage Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Passage Bio Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Passage Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Passage Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Passage Bio (PASG) has a Debt-to-Equity of 0.49 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Passage Bio and its competitors. This is 96% above median its historical median of 0.25. Over the past decade, Passage Bio's Debt-to-Equity has ranged from 0.10 to 1.28. According to the industry distribution chart, Passage Bio ranks #723 out of 966 companies in the Biotechnology industry, placing it in the top 74.8%.
Is Passage Bio's Debt-to-Equity too high?
Passage Bio's current Debt-to-Equity of 0.49 is 96% above median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.28. The Biotechnology industry median Debt-to-Equity is 0.16. Passage Bio's value of 0.49 is 206.3% above this industry median. Based on the distribution chart, Passage Bio ranks #723 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Debt-to-Equity compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #723 out of 966 companies for Debt-to-Equity. This places Passage Bio in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Passage Bio's value of 0.49 is 206.3% above this benchmark. Historically, Passage Bio's own Debt-to-Equity has ranged from 0.10 to 1.28 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 0.16, Passage Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Passage Bio's current Debt-to-Equity of 0.49 is 206.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Passage Bio and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current Debt-to-Equity is 0.49, which is 96% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Debt-to-Equity of 0.49. The current Debt-to-Equity is 0.49, which is 96% above median its 10-year median of 0.25 and 206.3% above the Biotechnology industry median of 0.16. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Passage Bio (PASG), the current Debt-to-Equity is 0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score
Get the complete analysis for PASG
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASG has been successfully added to your 
